At a glance
Effects
- Slow-wave (delta) sleep: Synthetic DSIP increased EEG delta activity by about 35% after intraventricular infusion in rabbits; it appears to modulate sleep architecture rather than sedate [5]. Human evidence is old, small and weak [1][6].
- Sleep continuity (modest, uncertain): A double-blind IV trial in chronic insomniacs found higher sleep efficiency and shorter sleep latency vs placebo, but effects were weak and authors concluded short-term DSIP is unlikely to be of major therapeutic benefit [1].
- Stress-hormone modulation: In animals DSIP altered substance P, beta-endorphin and corticosterone levels, suggesting a stress-coping / neuroendocrine role [10].
- Neuroprotection (animal only): A 2021 rat study reported DSIP accelerated motor recovery after focal stroke; it has also shown antiedematic and anticonvulsant activity in animals [11][9].
Synthetic neuropeptide (9-amino-acid; research chemical)
Not approved anywhere; FDA safety-concern list
IV in trials; subcutaneous in community use
Rapidly degraded by aminopeptidases in plasma
~850 daltons (C35H48N10O15)
About Delta sleep-inducing peptide
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Delta sleep-inducing peptide (DSIP) is a small nine-amino-acid neuropeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits in 1977 and originally proposed as a sleep-promoting factor [1][2][5]. It is not an approved medicine anywhere; it is sold and used as a research chemical, not for human consumption [7][9].
How it works
DSIP's mechanism is genuinely not understood — almost fifty years after its discovery, no DSIP gene, precursor protein, or dedicated receptor has been identified, which is why a leading review calls it "a still unresolved riddle" [3][6]. In animal studies it appears to modulate neurotransmission: it dose-dependently potentiates GABA-activated currents while blocking NMDA-receptor potentiation in cortical and hippocampal neurons, and its central actions may be mediated via NMDA receptors [2][4]. It has also been linked to neuroendocrine and stress-hormone regulation rather than acting as a simple sedative [2][9][10].
Risks & side effects
Most important: The biggest risk is the unknown: the FDA placed DSIP on its list of bulk drug substances with significant safety concerns, flagging a potential for immunogenicity (the immune system attacking the substance), and notes that no safety data establishing whether it is harmful to humans has been identified [9]. Because it is sold only as a research chemical, purity, sterility and labeling are unregulated and vary between vendors [7][9].
Common
Serious
Safety & harm reduction
- Anyone seeking an approved, tested medicine — DSIP is not approved for human use in any country [8][9][13]
- People who cannot accept unknown long-term safety and unregulated product quality [7][12]
- Patients around anaesthesia, given the unexpected reduction in anaesthetic depth seen in one human study [2]
- Sold as lyophilized powder; community practice reconstitutes with bacteriostatic water, stores refrigerated (2–8°C) and uses within ~28 days [8][11]
- If stacked with other peptides, community sources inject each separately rather than mixing in one syringe [8]
- Use only under a qualified clinician; verify current FDA/Emideltide regulatory status before sourcing [11][13]
Dosage context
There is no FDA-approved product and no official dosing guideline [13]. Published human efficacy trials used short intravenous courses (e.g. 25 nmol/kg in chronic insomniacs); community/research-use protocols instead describe subcutaneous dosing (commonly around 250 mcg) taken 1–3 hours before sleep — note that the bioavailability difference between IV and subcutaneous is unknown given DSIP's rapid degradation [1][8][11]. These are commonly-reported figures, not a prescription, and dosing should be set by a prescribing clinician [13].
Sources
- 1.PubChem — Delta Sleep-Inducing Peptide (CID 68816)
- 2.Wikipedia — Delta-sleep-inducing peptide
- 3.Kovalzon & Strekalova, DSIP: a still unresolved riddle (J Neurochem 2006, PubMed)
- 4.Effects of DSIP on glutamate/GABA receptors in rats (PubMed)
- 5.Schoenenberger & Monnier, DSIP isolation/synthesis nonapeptide (PubMed)
- 6.Effects of DSIP on sleep of chronic insomniac patients, double-blind (PubMed)
- 7.Exploring Peptides — DSIP regulatory/quality status
- 8.The Peptide Catalog — DSIP dosing/safety review
- 9.Innerbody — DSIP full rundown (FDA safety-concern list, immunogenicity)
- 10.DSIP and resistance to emotional stress (PubMed)
- 11.Peptide Dosing Protocols — DSIP route/monitoring/regulatory
- 12.Swolverine — DSIP benefits, dosage and risks
- 13.Rite Aid — DSIP benefits, dosage & 2026 legal status
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.